$STRM
STREAMLINE HEALTH SOLUTIONS INC.

2024 Q4 Form 10-Q Financial Statement

#000143774924038124 Filed on December 20, 2024

View on sec.gov

Income Statement

Concept 2024 Q4
Revenue $4.419M
YoY Change -27.95%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.880M
YoY Change -30.13%
% of Gross Profit
Research & Development $1.134M
YoY Change -13.04%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $4.014M
YoY Change -26.02%
Operating Profit -$1.980M
YoY Change -84.71%
Interest Expense $496.0K
YoY Change 86.47%
% of Operating Profit
Other Income/Expense, Net $0.00
YoY Change
Pretax Income -$2.476M
YoY Change -79.42%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$2.476M
YoY Change -79.21%
Net Earnings / Revenue -56.03%
Basic Earnings Per Share -$0.61
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding 4.055M
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $754.0K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables $2.824M
Other Receivables
Total Short-Term Assets $5.393M
YoY Change -30.1%
LONG-TERM ASSETS
Property, Plant & Equipment $52.00K
YoY Change -44.68%
Goodwill $13.28M
YoY Change 0.0%
Intangibles $10.84M
YoY Change -13.1%
Long-Term Investments
YoY Change
Other Assets $1.236M
YoY Change -4.41%
Total Long-Term Assets $30.57M
YoY Change -8.44%
TOTAL ASSETS
Total Short-Term Assets $5.393M
Total Long-Term Assets $30.57M
Total Assets $35.97M
YoY Change -12.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.610M
YoY Change 118.75%
Accrued Expenses $1.518M
YoY Change -47.35%
Deferred Revenue $6.095M
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.85M
YoY Change -6.58%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $10.20M
YoY Change 17.68%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.85M
Total Long-Term Liabilities $10.20M
Total Liabilities $22.05M
YoY Change 3.27%
SHAREHOLDERS EQUITY
Retained Earnings -$123.7M
YoY Change 8.21%
Common Stock $43.00K
YoY Change -99.97%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $13.91M
YoY Change
Total Liabilities & Shareholders Equity $35.97M
YoY Change -12.5%

Cashflow Statement

Concept 2024 Q4
OPERATING ACTIVITIES
Net Income -$2.476M
YoY Change -79.21%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001008586
dei Entity Registrant Name
EntityRegistrantName
STREAMLINE HEALTH SOLUTIONS INC.
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--01-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2025
CY2024Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
59000 usd
CY2024Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
86000 usd
CY2024Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
328000 usd
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
291000 usd
CY2024Q4 us-gaap Capitalized Computer Software Accumulated Amortization
CapitalizedComputerSoftwareAccumulatedAmortization
9368000 usd
CY2024Q1 us-gaap Capitalized Computer Software Accumulated Amortization
CapitalizedComputerSoftwareAccumulatedAmortization
7960000 usd
CY2024Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
5246000 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4019000 usd
CY2024Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
85000000
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
85000000
CY2024Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4265821
CY2024Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4265821
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3929446
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3929446
us-gaap Amortization Of Deferred Sales Commissions
AmortizationOfDeferredSalesCommissions
383000 usd
strm Deferred Sales Commissions Impairment Loss
DeferredSalesCommissionsImpairmentLoss
93000 usd
strm Deferred Sales Commissions Impairment Loss
DeferredSalesCommissionsImpairmentLoss
35000 usd
CY2022Q4 us-gaap Debt Instrument Variable Interest Rate Type Extensible Enumeration
DebtInstrumentVariableInterestRateTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#PrimeRateMember
CY2024Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-10-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-28132
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
31-1455414
dei Entity Address Address Line1
EntityAddressAddressLine1
2400 Old Milton Pkwy., Box 1353
dei Entity Address City Or Town
EntityAddressCityOrTown
Alpharetta
dei Entity Address State Or Province
EntityAddressStateOrProvince
GA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
30009
dei City Area Code
CityAreaCode
888
dei Local Phone Number
LocalPhoneNumber
997-8732
dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value per share
dei Trading Symbol
TradingSymbol
STRM
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4273175
CY2024Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
754000 usd
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3190000 usd
CY2024Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2824000 usd
CY2024Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4237000 usd
CY2024Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
1248000 usd
CY2024Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
780000 usd
CY2024Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
567000 usd
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
629000 usd
CY2024Q4 us-gaap Assets Current
AssetsCurrent
5393000 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
8836000 usd
CY2024Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
52000 usd
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
88000 usd
CY2024Q4 us-gaap Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
5165000 usd
CY2024Q1 us-gaap Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
5798000 usd
CY2024Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
10844000 usd
CY2024Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
12071000 usd
CY2024Q4 us-gaap Goodwill
Goodwill
13276000 usd
CY2024Q1 us-gaap Goodwill
Goodwill
13276000 usd
CY2024Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1236000 usd
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1666000 usd
CY2024Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
30573000 usd
CY2024Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
32899000 usd
CY2024Q4 us-gaap Assets
Assets
35966000 usd
CY2024Q1 us-gaap Assets
Assets
41735000 usd
CY2024Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1610000 usd
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1253000 usd
CY2024Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1518000 usd
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2023000 usd
CY2024Q4 us-gaap Loans Payable Current
LoansPayableCurrent
2250000 usd
CY2024Q1 us-gaap Loans Payable Current
LoansPayableCurrent
1500000 usd
CY2024Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
6095000 usd
CY2024Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
7112000 usd
CY2024Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
377000 usd
CY2024Q1 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
1794000 usd
CY2024Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11850000 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
13682000 usd
CY2024Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
5883000 usd
CY2024Q1 us-gaap Long Term Loans Payable
LongTermLoansPayable
7566000 usd
CY2024Q4 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
0 usd
CY2024Q1 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
1500000 usd
CY2024Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
4129000 usd
CY2024Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0 usd
CY2024Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
190000 usd
CY2024Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
173000 usd
CY2024Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
10202000 usd
CY2024Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
9239000 usd
CY2024Q4 us-gaap Liabilities
Liabilities
22052000 usd
CY2024Q1 us-gaap Liabilities
Liabilities
22921000 usd
CY2024Q4 us-gaap Common Stock Value
CommonStockValue
43000 usd
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
39000 usd
CY2024Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
137588000 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
134474000 usd
CY2024Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-123717000 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-115699000 usd
CY2024Q4 us-gaap Stockholders Equity
StockholdersEquity
13914000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
18814000 usd
CY2024Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
35966000 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
41735000 usd
CY2024Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4419000 usd
CY2023Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6133000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13226000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17235000 usd
CY2024Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2880000 usd
CY2023Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4122000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9060000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
12079000 usd
CY2024Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1134000 usd
CY2023Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1304000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3569000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4310000 usd
CY2024Q4 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2023Q4 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
9813000 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
9813000 usd
CY2024Q4 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
CY2023Q4 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
963000 usd
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
963000 usd
CY2024Q4 us-gaap Costs And Expenses
CostsAndExpenses
6399000 usd
CY2023Q4 us-gaap Costs And Expenses
CostsAndExpenses
19080000 usd
us-gaap Costs And Expenses
CostsAndExpenses
19670000 usd
us-gaap Costs And Expenses
CostsAndExpenses
35776000 usd
CY2024Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-1980000 usd
CY2023Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-12947000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6444000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-18541000 usd
CY2024Q4 us-gaap Interest Expense
InterestExpense
496000 usd
CY2023Q4 us-gaap Interest Expense
InterestExpense
266000 usd
us-gaap Interest Expense
InterestExpense
1457000 usd
us-gaap Interest Expense
InterestExpense
781000 usd
CY2024Q4 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
0 usd
CY2023Q4 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
1182000 usd
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-115000 usd
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
1905000 usd
CY2024Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 usd
CY2023Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
31000 usd
CY2024Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2476000 usd
CY2023Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12031000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8018000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17386000 usd
CY2024Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-0 usd
CY2023Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-120000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-59000 usd
CY2024Q4 us-gaap Net Income Loss
NetIncomeLoss
-2476000 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-11911000 usd
us-gaap Net Income Loss
NetIncomeLoss
-8018000 usd
us-gaap Net Income Loss
NetIncomeLoss
-17327000 usd
CY2024Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.15
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.61
CY2024Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4055268
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3780689
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3981406
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3756420
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
18814000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 usd
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
-0 usd
CY2024Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
67000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
529000 usd
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
770000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
4000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2739000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
17303000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 usd
CY2024Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
-0 usd
CY2024Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
10000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
571000 usd
CY2024Q3 strm Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
0 usd
CY2024Q3 strm Adjustments To Additional Paid In Capital Warrant Liability Reclassification
AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityReclassification
837000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2803000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
15898000 usd
CY2024Q4 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 usd
CY2024Q4 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
-0 usd
CY2024Q4 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
-0 usd
CY2024Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
492000 usd
CY2024Q4 us-gaap Net Income Loss
NetIncomeLoss
-2476000 usd
CY2024Q4 us-gaap Stockholders Equity
StockholdersEquity
13914000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
35511000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 usd
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
-0 usd
CY2023Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
179000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
595000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2901000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
33062000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 usd
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
-0 usd
CY2023Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
73000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
630000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2515000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
31104000 usd
CY2023Q4 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 usd
CY2023Q4 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
-0 usd
CY2023Q4 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
19000 usd
CY2023Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
577000 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-11911000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
19751000 usd
us-gaap Net Income Loss
NetIncomeLoss
-8018000 usd
us-gaap Net Income Loss
NetIncomeLoss
-17327000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3594000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3264000 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
507000 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
0 usd
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-115000 usd
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
1905000 usd
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
0 usd
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-104000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1483000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1626000 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
9813000 usd
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
963000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-58000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-1003000 usd
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-4299000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
116000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
65000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
357000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
109000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-505000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-417000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1000000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2417000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2638000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2161000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
-0 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
47000 usd
us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
667000 usd
us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
1562000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-667000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1609000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1000000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
500000 usd
us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
1500000 usd
us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
-0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
100000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
4400000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 usd
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
0 usd
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
500000 usd
us-gaap Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
886000 usd
us-gaap Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
-0 usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
168000 usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
-0 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
77000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
271000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
869000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-271000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2436000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4041000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3190000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6598000 usd
CY2024Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
754000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2557000 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 pure
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Use of Estimates</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates and judgments, including those related to the recognition of revenue, share-based compensation, capitalization of software development costs, intangible assets, the allowance for credit losses, contingent consideration, and income taxes. Actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2024Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
159000 usd
CY2024Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4419000 usd
CY2023Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6133000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13226000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17235000 usd
CY2024Q4 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1253000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
5878000 usd
CY2024Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
30068000 usd
CY2024Q4 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.46 pure
CY2024Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2024Q4 us-gaap Deferred Costs Current And Noncurrent
DeferredCostsCurrentAndNoncurrent
68000 usd
CY2024Q1 us-gaap Deferred Costs Current And Noncurrent
DeferredCostsCurrentAndNoncurrent
77000 usd
CY2024Q4 us-gaap Accumulated Amortization Of Other Deferred Costs
AccumulatedAmortizationOfOtherDeferredCosts
147000 usd
CY2024Q1 us-gaap Accumulated Amortization Of Other Deferred Costs
AccumulatedAmortizationOfOtherDeferredCosts
102000 usd
us-gaap Amortization Of Deferred Charges
AmortizationOfDeferredCharges
44000 usd
us-gaap Amortization Of Deferred Charges
AmortizationOfDeferredCharges
59000 usd
CY2024Q4 us-gaap Amortization Of Deferred Charges
AmortizationOfDeferredCharges
11000 usd
CY2023Q4 us-gaap Amortization Of Deferred Charges
AmortizationOfDeferredCharges
24000 usd
CY2024Q4 strm Deferred Commission Costs Paid And Payable
DeferredCommissionCostsPaidAndPayable
1157000 usd
CY2024Q1 strm Deferred Commission Costs Paid And Payable
DeferredCommissionCostsPaidAndPayable
1461000 usd
CY2024Q4 us-gaap Amortization Of Deferred Sales Commissions
AmortizationOfDeferredSalesCommissions
141000 usd
CY2023Q4 us-gaap Amortization Of Deferred Sales Commissions
AmortizationOfDeferredSalesCommissions
129000 usd
us-gaap Amortization Of Deferred Sales Commissions
AmortizationOfDeferredSalesCommissions
450000 usd
CY2024Q4 strm Deferred Sales Commissions Impairment Loss
DeferredSalesCommissionsImpairmentLoss
93000 usd
CY2023Q4 strm Deferred Sales Commissions Impairment Loss
DeferredSalesCommissionsImpairmentLoss
35000 usd
CY2024Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
86000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-58000 usd
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
31000 usd
CY2024Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
59000 usd
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
132000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
96000 usd
CY2024Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
451000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1483000 usd
CY2023Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
517000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1626000 usd
CY2024Q4 us-gaap Net Income Loss
NetIncomeLoss
-2476000 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-11911000 usd
us-gaap Net Income Loss
NetIncomeLoss
-8018000 usd
us-gaap Net Income Loss
NetIncomeLoss
-17327000 usd
CY2024Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.15
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.61
CY2024Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4055268
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3780689
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3981406
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3756420
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
220327
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
132013
CY2023Q4 us-gaap Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
26 pure
CY2023Q4 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.24 pure
CY2023Q4 us-gaap Restructuring Costs
RestructuringCosts
759000 usd
CY2024Q3 us-gaap Restructuring Costs
RestructuringCosts
0 usd
CY2024Q1 us-gaap Restructuring Reserve
RestructuringReserve
74000 usd
us-gaap Restructuring Charges
RestructuringCharges
0 usd
us-gaap Payments For Restructuring
PaymentsForRestructuring
74000 usd
CY2024Q4 us-gaap Restructuring Reserve
RestructuringReserve
0 usd
CY2024Q4 us-gaap Restructuring And Related Cost Cost Incurred To Date1
RestructuringAndRelatedCostCostIncurredToDate1
759000 usd
CY2024Q4 us-gaap Restructuring And Related Cost Expected Cost1
RestructuringAndRelatedCostExpectedCost1
759000 usd
CY2023Q1 us-gaap Restructuring Reserve
RestructuringReserve
0 usd
us-gaap Restructuring Charges
RestructuringCharges
749000 usd
us-gaap Payments For Restructuring
PaymentsForRestructuring
-0 usd
CY2023Q4 us-gaap Restructuring Reserve
RestructuringReserve
749000 usd
CY2024Q4 us-gaap Stock Issued1
StockIssued1
41000 usd
us-gaap Stock Issued1
StockIssued1
109000 usd
CY2023Q4 us-gaap Stock Issued1
StockIssued1
60000 usd
us-gaap Stock Issued1
StockIssued1
176000 usd
strm Professional Fees Noncash
ProfessionalFeesNoncash
4000 usd
CY2024Q4 us-gaap Long Term Debt
LongTermDebt
8133000 usd
CY2024Q1 us-gaap Long Term Debt
LongTermDebt
9066000 usd
CY2024Q4 us-gaap Notes Payable
NotesPayable
4129000 usd
CY2024Q1 us-gaap Notes Payable
NotesPayable
0 usd
CY2024Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0 usd
CY2024Q1 us-gaap Notes Payable Current
NotesPayableCurrent
0 usd
CY2024Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
4129000 usd
CY2024Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
0 usd
CY2024Q1 strm Minimum Adjusted Ebitda
MinimumAdjustedEBITDA
-5750000 usd
CY2024Q2 strm Minimum Adjusted Ebitda
MinimumAdjustedEBITDA
-4560000 usd
CY2024Q3 strm Minimum Adjusted Ebitda
MinimumAdjustedEBITDA
-2960000 usd
CY2024Q4 strm Minimum Adjusted Ebitda
MinimumAdjustedEBITDA
-1500000 usd
CY2024Q2 strm Debt Instrument Maximum Debt To Apr Ratio
DebtInstrumentMaximumDebtToAPRRatio
0.5 pure
CY2024Q3 strm Debt Instrument Maximum Debt To Apr Ratio
DebtInstrumentMaximumDebtToAPRRatio
0.45 pure
CY2024Q4 strm Debt Instrument Maximum Debt To Apr Ratio
DebtInstrumentMaximumDebtToAPRRatio
0.4 pure
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-59000 usd
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.24 pure
CY2024Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
346000 usd
CY2024Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
340000 usd
us-gaap Number Of Reporting Units
NumberOfReportingUnits
1 pure
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
9813000 usd
CY2023Q1 us-gaap Goodwill
Goodwill
23089000 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
9813000 usd
CY2023Q4 us-gaap Goodwill
Goodwill
13276000 usd
CY2023Q4 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
963000 usd

Files In Submission

Name View Source Status
0001437749-24-038124-index-headers.html Edgar Link pending
0001437749-24-038124-index.html Edgar Link pending
0001437749-24-038124.txt Edgar Link pending
0001437749-24-038124-xbrl.zip Edgar Link pending
ex_730777.htm Edgar Link pending
ex_730778.htm Edgar Link pending
ex_730779.htm Edgar Link pending
ex_730780.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
strm-20241031.xsd Edgar Link pending
strm20241031_10q.htm Edgar Link pending
strm-20241031_lab.xml Edgar Link unprocessable
strm-20241031_pre.xml Edgar Link unprocessable
strm20241031_10q_htm.xml Edgar Link completed
strm-20241031_def.xml Edgar Link unprocessable
strm-20241031_cal.xml Edgar Link unprocessable